Medical technology company Neola Medical AB (NASDAQ First North Growth Market:NEOLA) said on Tuesday that it has been granted a US patent for its disposable probes used with the Neola medical device.

The advanced light and detector probes enable continuous lung monitoring of preterm infants, with two sets required daily to monitor both lungs, forming the basis of Neola Medical's recurring revenue model.

The US patent complements an already granted European patent, with a corresponding application pending in China.

CEO Hanna Sjöström highlighted that this patent strengthens the company's competitive position in its key market and safeguards its unique optical design.

The granted patent, part of the family 'A light diffuser and a method for assembling the same', protects the technology enabling uniform, diffuse light distribution from the dermal emitter probe. This design is critical for safe, non-invasive, and continuous lung monitoring using optical spectroscopy.